Country Outlook: Germany

Germany is recognised as one of the most developed and innovative countries in the world, and one the strongest market in the pharmaceutical sector.

The german pharma industry constitutes the major European pharmaceutical market and the fourth largest worldwide. Only after the United States, China and Japan.

Combining cutting edge-innovation, long traditional expertise in the pharma sector, and recognised as the “world´s pharmacy”, Germany demand of healthercare products is continuously growing. Becoming the ideal destination for pharmaceutical R&D, production, and business development.

With 83 million inhabitants, Europe’s most populous country also represents the biggest healthcare market in the euro region.

With an expenditure that is continuously rising, Germany offers interesting opportunities for international companies operating in the pharmaceutical market.

Between 2013 and 2018, the country’s healthcare expenditure grew by almost 4.4 percent per year on average. Reaching a new high of EUR 390.6 billion in 2018. Accounting for almost 12 percent of German GDP.

Driven by developments like demographic change, the growing prevalence of chronic diseases, and the Covid-19 outbreak, this upwards trend in annual German health expenditure is expected to continue, after exceeding the EUR 400 billion mark in 2019.